{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:36Z","timestamp":1791355776519,"version":"4.3.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemotherapy in patients with EGFR-mutant advanced lung adenocarcinoma and brain parenchymal metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A bicenter retrospective cohort study was conducted. A total of 150 eligible patients were enrolled and balanced by 1:1 propensity score matching. Tumor response, survival outcomes, and treatment-related adverse events were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 60 patients were assigned to each group. The intracranial objective response rate was 78.3% in the combination group\n                      <jats:italic>versus<\/jats:italic>\n                      61.7% in the monotherapy group (P = 0.046). The median intracranial progression-free survival was 28.3 months in the combination group (hazard ratio = 0.536, 95% confidence interval: 0.350\u20130.820, P = 0.002). Systemic progression-free survival and overall survival were also significantly prolonged in the combination arm. Adverse events were predominantly chemotherapy-related toxicities and were generally manageable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>First-line third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy is associated with superior intracranial and systemic survival benefits in EGFR-mutant lung adenocarcinoma patients with brain parenchymal metastases, with a favorable safety profile. This study provides real-world evidence to support clinical treatment decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1959801","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:33Z","timestamp":1791352233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy versus TKI monotherapy as first-line treatment for EGFR-mutant lung adenocarcinoma with brain parenchymal metastases"],"prefix":"10.3389","volume":"17","author":[{"given":"Jianxi","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Head, Neck and Thoracic Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine-Hebei","place":["Cangzhou, Hebei Province, China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fifth People\u2019s Hospital of Hengshui City","place":["Hengshui, Heibei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Wen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Qin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1448336","DOI":"10.3389\/fonc.2024.1448336","article-title":"The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-25-3431","article-title":"Patient-reported outcomes in FLAURA2: osimertinib with or without chemotherapy in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer","volume":"32","author":"Gray","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/cncr.34757","article-title":"Targeted therapy for lung cancer: beyond EGFR and ALK","volume":"129","author":"Herrera-Ju\u00e1rez","year":"2023","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2255050","DOI":"10.1001\/jamanetworkopen.2022.55050","article-title":"Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label, randomized, multicenter, phase 3 study","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1016\/j.tranon.2023.101832","article-title":"Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis","volume":"39","author":"Jia","year":"2024","journal-title":"Transl. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"103549","DOI":"10.1016\/j.jtho.2026.01.001","article-title":"Osimertinib and stereotactic radiosurgery for brain metastases in EGFR-mutated lung cancer: the STARLET joint analysis of OUTRUN and LUOSICNS randomized trials","volume":"21","author":"Lee","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"r1154","DOI":"10.1136\/bmj.r1154","article-title":"EGFR-Mutated non-small cell lung cancer","volume":"389","author":"Ma","year":"2025","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"22901","DOI":"10.1038\/s41598-024-74496-0","article-title":"First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.21.02911","article-title":"Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"40","author":"Miyauchi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11864-021-00911-7","article-title":"Systemic therapy for lung cancer brain metastases","volume":"22","author":"Pellerino","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","article-title":"Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies","volume":"18","author":"Popat","year":"2023","journal-title":"Target Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.21037\/tlcr-2025-502","article-title":"Molecular and clonal evolution of primary lesions vs. brain metastasis in EGFR-mutated NSCLC: a retrospective cohort study","volume":"14","author":"Ru\u00edz-Pati\u00f1o","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1297988","DOI":"10.3389\/fimmu.2023.1297988","article-title":"Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy","volume":"14","author":"Sereno","year":"2024","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14737140.2025.2591286","article-title":"EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-Mutant NSCLC with high PD-L1 expression: a real-world retrospective study","volume":"26","author":"Su","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B25","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"B26","doi-asserted-by":"publisher","first-page":"108641","DOI":"10.1016\/j.lungcan.2025.108641","article-title":"Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer","volume":"206","author":"Wang","year":"2025","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"598265","DOI":"10.3389\/fonc.2021.598265","article-title":"First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1959801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:34Z","timestamp":1791352234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1959801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":27,"alternative-id":["10.3389\/fphar.2026.1959801"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1959801","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1959801"}}